Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Drug Discovery > Online
NEWS & BUZZ   Open Access     Cite

Limertinib: The third-generation EGFR-TKI developed in China for the treatment of EGFR-Mutated non-small cell lung cancer

  • 1.

    Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou 215006, China

  • 2.

    College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China

More Information
  • Corresponding author: zwyan@suda.edu.cn
  • Received Date:  July 11, 2026
    Accepted Date:  September 03, 2026
    Published Online:  September 10, 2026
The Innovation Drug Discovery  https://doi.org/10.59717/j.xinn-drugdisc.2026.100038  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Zhang T, Qu R, Chan S, et al. (2020). Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol. Cancer 19:90. DOI:10.1186/s12943-020-01202-9

    View in Article CrossRef Google Scholar

    [2] Shi Y, Li B, Wu L, et al. (2022). Efficacy and safety of limertinib (ASK120067) in patients with locally advanced or metastatic EGFR Thr790Met-mutated NSCLC: A multicenter, single-arm, Phase 2b study. J. Thorac. Oncol. 17:1205−1215. DOI:10.1016/j.jtho.2022.05.011

    View in Article CrossRef Google Scholar

    [3] Shi Y, Wu L, Ji Y, et al. (2025). Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir. Med. 13:677−686. DOI:10.1016/S2213-2600(25)00121-3

    View in Article CrossRef Google Scholar

    [4] Jänne PA, Planchard D, Kobayashi K, et al. (2026). Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N. Eng. J. Med. 394:27−38. DOI:10.1056/NEJMoa2510308

    View in Article CrossRef Google Scholar

    [5] Liu X, Zhao Q, Sun W, Chen J. (2026). First-line third-generation EGFR-TKIs for advanced EGFR-mutated non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials. J. Thorac. Dis. 18:617. DOI:10.21037/jtd-2026-1-0317

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Ren S., Zhang Y., Shao Y., et al. (2026). Limertinib: The third-generation EGFR-TKI developed in China for the treatment of EGFR-Mutated non-small cell lung cancer. The Innovation Drug Discovery 1:100038. https://doi.org/10.59717/j.xinn-drugdisc.2026.100038
    Ren S., Zhang Y., Shao Y., et al. (2026). Limertinib: The third-generation EGFR-TKI developed in China for the treatment of EGFR-Mutated non-small cell lung cancer. The Innovation Drug Discovery 1:100038. https://doi.org/10.59717/j.xinn-drugdisc.2026.100038

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(271) PDF downloads(47)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Published articles are licensed under CC BY with copyright retained by the authors.
    All contents on this site: Copyright © 2026 INNOVATION PRESS. All rights are reserved.